Illumina ordered to pay Chinese company $333 million in gene-sequencing patent case
2022.05.06 23:51
FILE PHOTO: A new office building housing genetic research company Illumina is shown in San Diego, California, U.S., May 30, 2018. REUTERS/Mike Blake
By Blake Brittain
(Reuters) – A Delaware jury on Friday ordered Illumina Inc (NASDAQ:ILMN) to pay more than $333 million to a U.S. unit of Chinese genetic analysis company BGI Genomics after finding that Illumina’s DNA-sequencing systems infringed two patents.
The jury also said Illumina infringed the patents willfully, and that three patents it had accused BGI’s Complete Genomics unit of infringing were invalid.
BGI and Illumina have been embroiled in a global legal battle over their respective sequencing technologies.
Illumina previously won $8 million from BGI in a jury verdict in San Francisco and a ban on U.S. sales of some BGI products.
In the Delaware case, San Jose, California-based Complete Genomics Inc, a BGI subsidiary, had challenged Illumina’s “two-channel” sequencing systems and kits to prepare DNA fragments for sequencing of violating its patent rights.
An Illumina spokesperson said the company plans to appeal and that the verdict should not affect its ability to supply its customers.
An attorney for CGI said the company was pleased with the verdict.
